Aktienanalyse zu Rani Therapeutics Holdings Inc (RANI)RANIRani Therapeutics Holdings Inc

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Rani Therapeutics Holdings Inc is not a good buy right now due to its current price of $0.5518, which is close to its 52-week low of $0.55, and an extremely low RSI of 17.633 indicating oversold conditions. The company has reported a net loss of $8.4 million for Q2 2026, and its stock has seen a year-to-date decline of 59.43%.